AG真人官方

Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA

REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- 聽(OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity鈥檚 Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors.

Event: Biotricity Fiscal 2026 First Quarter Financial Results and Business Update Call
Date: Thursday August 14, 2025
Time: 4:30 PM ET (1:30 PM PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL:听

Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.

A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at聽.

Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13755374
Expiration: Thursday, August 28, 2025聽at 11:59 PM ET

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity鈥檚 unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit聽.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words 鈥渕ay,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渨ill,鈥� 鈥渃ould,鈥� 鈥渟cheduled,鈥� 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥渂elieve,鈥� 鈥渋ntend,鈥� 鈥渟eek,鈥� 鈥減roject,鈥� or 鈥済oal鈥� or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company鈥檚 other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company鈥檚 future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company鈥檚 current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company鈥檚 inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company鈥檚 inability to expand the Company鈥檚 business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company鈥檚 failure to implement the Company鈥檚 business plans or strategies. These and other factors are identified and described in more detail in the Company鈥檚 filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:
Investor relations:
Biotricity Investor Relations